Amylyx Pharmaceuticals Financial Statements (AMLX)
|
|
|
|
Report date
|
|
|
07.08.2025 |
06.11.2025 |
03.03.2026 |
07.05.2026 |
06.08.2026 |
|
07.05.2026 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
Operating Income, bln rub |
|
|
-42.9 |
-36.0 |
-36.6 |
-43.8 |
-45.7 |
|
-159.3 |
|
EBITDA, bln rub |
? |
|
-41.3 |
-34.3 |
-30.9 |
-41.2 |
-43.4 |
|
-150.3 |
|
Net profit, bln rub |
? |
|
-41.4 |
-34.4 |
-33.0 |
-41.3 |
-43.4 |
|
-150.1 |
|
|
OCF, bln rub |
? |
|
-25.2 |
-30.4 |
-27.9 |
-36.9 |
-31.4 |
|
-120.4 |
|
CAPEX, bln rub |
? |
|
0.017 |
0.024 |
0.086 |
0.000 |
0.030 |
|
0.127 |
|
FCF, bln rub |
? |
|
-25.3 |
-30.4 |
-28.0 |
-36.9 |
-31.5 |
|
-120.5 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
42.7 |
16.2 |
36.5 |
43.8 |
45.7 |
|
139.2 |
|
Cost of production, bln rub |
|
|
0.141 |
19.9 |
0.108 |
0.098 |
0.000 |
|
20.2 |
|
R&D, bln rub |
|
|
27.1 |
19.9 |
21.1 |
27.6 |
23.8 |
|
95.6 |
|
Interest expenses, bln rub |
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Assets, bln rub |
|
|
194.6 |
362.7 |
332.6 |
293.6 |
264.6 |
|
293.6 |
|
Net Assets, bln rub |
? |
|
167.9 |
332.0 |
305.3 |
273.2 |
239.2 |
|
273.2 |
|
Debt, bln rub |
|
|
5.96 |
5.94 |
5.96 |
5.63 |
5.26 |
|
5.63 |
|
Cash, bln rub |
|
|
180.8 |
344.0 |
317.0 |
279.8 |
250.8 |
|
279.8 |
|
Net debt, bln rub |
|
|
-174.9 |
-338.1 |
-311.0 |
-274.1 |
-245.5 |
|
-274.1 |
|
|
Ordinary share price, rub |
|
|
6.41 |
13.6 |
12.1 |
13.9 |
18.0 |
|
15.7 |
|
Number of ordinary shares, mln |
|
|
89.1 |
93.3 |
94.6 |
110.6 |
111.2 |
|
110.6 |
|
|
Market cap, bln rub |
|
|
571 |
1 268 |
1 142 |
1 537 |
1 997 |
|
1 733 |
|
EV, bln rub |
? |
|
397 |
930 |
831 |
1 263 |
1 752 |
|
1 458 |
|
Book value, bln rub |
|
|
168 |
332 |
305 |
273 |
239 |
|
273 |
|
|
EPS, rub |
? |
|
-0.46 |
-0.37 |
-0.35 |
-0.37 |
-0.39 |
|
-1.36 |
|
FCF/share, rub |
|
|
-0.28 |
-0.33 |
-0.30 |
-0.33 |
-0.28 |
|
-1.09 |
|
BV/share, rub |
|
|
1.88 |
3.56 |
3.23 |
2.47 |
2.15 |
|
2.47 |
|
|
FCF yield, % |
? |
|
-29.0% |
-12.2% |
-10.8% |
-7.84% |
-6.35% |
|
-6.96% |
|
ROE, % |
? |
|
-111.7% |
-45.0% |
-47.4% |
-55.0% |
-63.6% |
|
-55.0% |
|
ROA, % |
? |
|
-96.4% |
-41.2% |
-43.5% |
-51.1% |
-57.5% |
|
-51.1% |
|
|
P/E |
? |
|
-3.05 |
-8.50 |
-7.89 |
-10.2 |
-13.1 |
|
-11.5 |
|
P/FCF |
|
|
-3.45 |
-8.21 |
-9.25 |
-12.8 |
-15.8 |
|
-14.4 |
|
P/S |
? |
|
0.00 |
0.00 |
|
|
|
|
|
|
P/BV |
? |
|
3.40 |
3.82 |
3.74 |
5.63 |
8.35 |
|
6.34 |
|
EV/EBITDA |
? |
|
-2.03 |
-6.05 |
-5.77 |
-8.55 |
-11.7 |
|
-9.70 |
|
Debt/EBITDA |
|
|
0.90 |
2.20 |
2.16 |
1.86 |
1.64 |
|
1.82 |
|
|
R&D/CAPEX, % |
|
|
159 271% |
82 729% |
24 541% |
|
79 227% |
|
75 312% |
|
| Amylyx Pharmaceuticals shareholders |
